Major digital health companies are steadily moving away from single-task capabilities to capture larger volumes of personal medical information. Epic is expanding beyond its traditional record-keeping role to generate direct clinical recommendations, while ambient documentation platform Abridge is gathering patient insurance details. Meanwhile, OpenEvidence is shifting from answering general clinical queries to requesting full patient records and visit histories for tailored guidance. These industry-wide changes and their broader implications will be addressed by commercial and clinical leaders at the upcoming HLTH conference.
Key points
Health technology vendors are moving away from single-task artificial intelligence system…: Health technology vendors are moving away from single-task artificial intelligence systems toward broad data integration.
Clinical platforms increasingly demand comprehensive patient files to provide customized…: Clinical platforms increasingly demand comprehensive patient files to provide customized guidance rather than generic medical answers.
Industry leaders from organizations like Novartis, Johnson & Johnson, and Epic will exami…: Industry leaders from organizations like Novartis, Johnson & Johnson, and Epic will examine these changing technologies at the HLTH conference.
Sources checked by our analysis pipeline: 1
Let me know if, especially after reading the below item on what recent heart drug failures mean for AI in drug discovery, you have questions about AI in pharma. I’ll be interviewing executives from Novartis and Johnson & Johnson on stage next week at the HLTH conference.
And if you have questions for Epic, come on down to the STAT stage takeover at HLTH a week from today, where I’ll be talking to Aneesh Chopra, Brendan Keeler, and Epic executives Antonia Papajani and Seth Howard.
Less is more?
In today’s clinical AI landscape, every platform is making a land grab: Epic, traditionally a system of record, now wants to display clinical recommendations. Abridge, which started as an ambient scribe, wants your patient’s insurance information. OpenEvidence, which originally answered clinical questions, wants you to enter patient records and visits so it can give you personalized recommendations.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
The cross-border startup is targeting the growing enterprise ecosystem by designing specialized analytics infrastructure tailored to autonomous digital software. This substantial launch capital allows the team to scale development across its dual headquarters in Israel and California. The move signals heightened investor appetite for back-end data architectures built expressly to serve next-generation artificial intelligence workflows.
To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.
The system was developed using training data from more than 100 million cell profiles spanning 68 different tissues. It aims to support scientific efforts to understand how variations in genetic code impact biological functions across various tissue types.